Protective effect of HSP27 in atherosclerosis and coronary heart disease by inhibiting reactive oxygen species

Abstract

HSP27 exerts its protective role by suppressing ROS and AS progression by inhibiting mitochondria apoptosis pathway in CHD.

Circulating heat shock protein 27 as a novel marker of subclinical atherosclerosis in type 2 diabetes: a cross-sectional community-based study

“…Contrary to these results, circulating HSP27 levels were reported as decreased >70% in patients with carotid stenosis [8] and coronary artery diseases (CAD) compared with healthy subjects [25]. In addition to reduced concentrations of HSP27, patients with CAD in these two studies had more severe comorbidities compared to patients with higher HSP27 level in Park's and Zhang HL's studies [23,24], including diabetes and hypertension in both studies and smoking in the former plus hyperlipemia in the latter. Patients in these two studies had serum HSP27 levels even decreased to a mean value of 0.19 ng/mL and 1.23 ng/mL, respectively.…”

“…Similarly, Park et al reported that circulating HSP27 levels in acute coronary syndrome (ACS) patients were remarkably higher than those in an age-and sex-matched healthy control group [23]. Compared with controls, a significant increase in serum HSP27 in patients with CHD was also observed in a recent study [24].…”

“…The degradation of extracellular HSP27 by proteases such as upregulated plasmin in plaque [26] and matrix metalloproteases (MMPs)[27, 28] may also have accounted for the decline in serum HSP27. In the progression of arthrosclerosis, the degradation of extracellular HSP27 by proteases such as upregulated plasmin in plaques [24], matrix metalloproteases (MMPs) [49,50] accounted for the subsequent decline of serum HSP27.…”

Circulating heat shock protein 27 as a novel marker of subclinical atherosclerosis in type 2 diabetes: a cross-sectional community-based study

“…Contrary to these results, circulating HSP27 levels were reported as decreased >70% in patients with carotid stenosis [8] and coronary artery diseases (CAD) compared with healthy subjects [25]. In addition to reduced concentrations of HSP27, patients with CAD in these two studies had more severe comorbidities compared with patients having higher HSP27 levels in the studies of Park et al and Zhang et al [23,24], including diabetes and hypertension in both studies and smoking in the former plus hyperlipemia in the latter. Patients in these two studies even had serum HSP27 levels decreased to mean values of 0.19 ng/mL and 1.23 ng/mL, respectively.…”

“…Similarly, Park et al reported that circulating HSP27 levels in acute coronary syndrome (ACS) patients were remarkably higher than those in an age-and sex-matched healthy controls [23]. Compared with controls, a significant increase in serum HSP27 in patients with CHD was also observed in a recent study [24].…”